Clinical Trial

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Ascending Doses of ABBV-1451 Infusions and Injections in Healthy Adult Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The objective of this study is to assess the pharmacokinetic (PK), immunogenicity, safety, and tolerability of ABBV-1451 after single ascending doses in healthy adult volunteers.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-29
Trial Details
NCT Number NCT07570147
Lead Sponsor AbbVie
Conditions Healthy Volunteer
Enrollment 90 participants
Start Date 2026-05-01
Primary Completion 2027-04 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2026-05-28